GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RespireRx Pharmaceuticals Inc (OTCPK:RSPI) » Definitions » 5-Year Yield-on-Cost %

RespireRx Pharmaceuticals (RespireRx Pharmaceuticals) 5-Year Yield-on-Cost % : 0.00 (As of May. 24, 2024)


View and export this data going back to 2009. Start your Free Trial

What is RespireRx Pharmaceuticals 5-Year Yield-on-Cost %?

RespireRx Pharmaceuticals's yield on cost for the quarter that ended in Sep. 2023 was 0.00.


The historical rank and industry rank for RespireRx Pharmaceuticals's 5-Year Yield-on-Cost % or its related term are showing as below:



RSPI's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.73
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Competitive Comparison of RespireRx Pharmaceuticals's 5-Year Yield-on-Cost %

For the Biotechnology subindustry, RespireRx Pharmaceuticals's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


RespireRx Pharmaceuticals's 5-Year Yield-on-Cost % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RespireRx Pharmaceuticals's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where RespireRx Pharmaceuticals's 5-Year Yield-on-Cost % falls into.



RespireRx Pharmaceuticals 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of RespireRx Pharmaceuticals is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5

RespireRx Pharmaceuticals  (OTCPK:RSPI) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


RespireRx Pharmaceuticals 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of RespireRx Pharmaceuticals's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.


RespireRx Pharmaceuticals (RespireRx Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
126 Valley Road, Suite C, Glen Rock, NJ, USA, 07452
RespireRx Pharmaceuticals Inc is engaged in the discovery, development, and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders. The pipeline products of the company are dronabinol which is developed for the treatment of OSA (Obstructive Sleep Apnea), a form of sleep apnea; CX1739 for the treatment of chronic central sleep apnea; CX717 and CX1942 is an injectable dosage for respiratory depression or vaso-occlusive passes associated with sickle cell disease. The company also focuses on developing another class of compounds called ampakines for the treatment of various respiratory disorders.
Executives
David Dickason officer: SVP of Pre-Clinical Prod. Dev. 126 VALLEY ROAD, SUITE C, GLEN ROCK NJ 07452
Timothy L. Jones director, officer: CEO and President 126 VALLEY ROAD, SUITE C, GLEN ROCK NJ 07452
Manuso James S J director, officer: President & CEO 5130 ROUTE 212, WILLOW NY 12495
Katie Macfarlane director 101 POOR FARM ROAD 3RD FLOOR, PRINCETON NJ 08540
Purcell Richard David Jr. officer: SVP - Research & Deleopment 65 FAIR HAVEN ROAD, FAIR HAVEN NJ 07704
James Sapirstein director 1517 SAN JACINTO, HOUSTON TX 77002
Marc M Radin officer: Controller 33 FRANKLIN PLACE, GLEN ROCK NJ 07452
Robert N Weingarten director, officer: Vice President and CFO 5439 LOCKHURST DRIVE, WOODLAND HILLS CA 91367
Aurora Capital Llc other: Member of a 10% owner group 354 WIDOW GAVITS ROAD, PO BOX 1167, BRIDGEHAMPTON, NY 11932-1167
Aurora Capital Corp other: Member of 10% owner group
Jeff Eliot Margolis director, officer: Vice President, Sec. & Treas., other: Member of 10% owner group C/O AURORA CAPITAL LLC, 17 PARK AVENUE, #201, NEW YORK NY 10016
Steven Chizzik other: Member of 10% owner group C/O THE VERRAZANO GROUP, LLC, 2204 MORRIS AVENUE, SUITE 203A, UNION NJ 07083
Arnold Lippa director, officer: Chairman, CEO and President, other: Member of 10% owner group C/O AURORA CAPITAL, LLC, 17 PARK AVENUE, #201, NEW YORK NY 10016
T. Morgen Capital Llc other: Member of 10% owner group C/O AURORA CAPITAL LLC, 17 PARK AVENUE, #201, NEW YORK NY 10016
Kenneth M Cohen other: Member of 10% owner group 12750 HIGH BLUFF DRIVE, SUITE 310, SAN DIEGO CA 92130

RespireRx Pharmaceuticals (RespireRx Pharmaceuticals) Headlines

From GuruFocus